Search Bar & Filters
Found 109 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating the effectiveness of the drug cemiplimab as adjuvant immunotherapy for patients with stage II-IIIA non-small cell lung cancer NSCLC who have had their tumors surgically removed and who have not received prior chemotherapy. This phase III trial focuses on comparing cemiplimab treatment to observation alone, specifically in patients whose tumors show PD-L1 expression of 1% or higher. The main goal is to measure disease-free survival, which means the time patients remain free from cancer recurrence or death. Participants in the experimental group receive cemiplimab intravenously at 350 mg every 3 weeks for 4 cycles, followed by 700 mg every 6 weeks for up to 6 cycles or until cancer returns or unacceptable side effects occur. Another group is assigned to observation without additional treatment. The study treatment schedules include specific dosing intervals and duration, designed to monitor the impact of cemiplimab on preventing cancer recurrence after surgery. Throughout the trial, participants will be monitored regularly for disease recurrence and side effects. Assessments include tracking disease-free survival and overall survival for up to approximately 59 months from randomization. Safety will be evaluated by documenting adverse events from the time of informed consent until the trial ends. Participants must comply with scheduled visits and testing to help researchers collect information on treatment effects and safety over the long term.
Actively Recruiting
Researchers are evaluating the combination of rituximab and golcadomide CC-99282 as a front-line, chemo-free treatment for older frail patients newly diagnosed with Diffuse Large B-Cell Non-Hodgkin Lymphoma DLBCL. This phase II, multicenter study focuses on patients aged 80 years or older who are considered frail based on a simplified geriatric assessment sGA and are not candidates for standard anthracycline-based chemotherapy. The study aims to assess efficacy and safety in this vulnerable population. Participants will receive an induction phase consisting of up to 6 cycles, each lasting 28 days. Cycle 1 includes rituximab intravenously on days 1, 8, and 15, golcadomide orally for days 1 to 14, and dexamethasone orally on days 1, 8, 15, and 22. Cycles 2 through 6 involve rituximab on day 1 and golcadomide orally for days 1 to 14. After induction, patients showing at least a partial response may undergo a consolidation phase starting within 6 to 8 weeks, receiving golcadomide orally for up to 6 more cycles. Involved site radiotherapy is permitted at the end of induction for PET-positive areas and may coincide with consolidation treatment. Throughout the study, patients will undergo response assessments after the 4th and 6th induction cycles and midway through consolidation to evaluate disease progression. Imaging such as PETCT or CT scans will be used for response and sarcopenia assessments. Quality of life will be measured at baseline and at multiple points during and after treatment. Follow-up monitoring will continue for 24 months, with visits every 3 months during the first year and every 6 months during the second year. Patients experiencing disease progression will be followed for survival until study completion. The primary outcome is progression-free survival at 24 months.
Actively Recruiting
Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are investigating the safety and effectiveness of the Renzan14 Peripheral Stent System in treating patients with femoro-popliteal disease, a type of peripheral arterial disease affecting the leg arteries. This prospective, multicenter, single-arm study plans to include about 100 patients eligible for treatment with this stent. The study focuses on evaluating a modern nitinol stent designed for complex lesions where drug-coated balloons and drug-eluting stents may be less effective or raise concerns about toxicity. The Renzan stent is a self-expanding nitinol device pre-mounted on a catheter designed for precise placement in the affected arteries. It consists of two layers of braided nitinol wire mesh with radiopaque markers to assist in positioning during the procedure. The stent can be partly recaptured during placement if needed. This study observes patients undergoing endovascular implantation of the Renzan stent without comparison groups, focusing on the devices performance and safety after treatment. Participants will be followed for assessments of safety and effectiveness, including measurements at 30 days and up to 12 months after the procedure. Key evaluations include device and procedural success during implantation, rates of death, need for further treatment of the treated artery, artery openness, limb ischemia improvement, major adverse events, and limb amputation at multiple time points up to 36 months. Patients will be monitored closely with follow-up visits to track these outcomes and the long-term performance of the stent.
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
Researchers are conducting an observational, multicenter, prospective study to evaluate the effects of benralizumab in adult patients with severe eosinophilic asthma. The study focuses on assessing the achievement of partial and complete clinical remission as defined by the Severe Asthma Network in Italy SANI. It also aims to deepen understanding of benralizumabs immunological effects and contribute to knowledge about asthma pathophysiology while consolidating long-term safety data. Participants in this study are patients treated with benralizumab, administered as 30mg subcutaneous injections according to the approved prescribing information. The study observes patients who have started or are about to start benralizumab treatment within a specific timeframe around enrollment. This real-life study does not involve assigning treatments but follows patients receiving benralizumab in clinical practice. During the study, participants will be monitored over up to 24 months to track clinical remission rates, asthma exacerbations, lung function changes, asthma control test scores, and medication use. Various assessments including lung function tests and questionnaires will be collected at baseline and multiple time points throughout the follow-up. The study aims to provide detailed real-world data on benralizumabs role in managing severe eosinophilic asthma.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
1-10 of 109
1